Anlotinib plus immunotherapy after standard treatment for extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at whether adding a targeted therapy called anlotinib to immunotherapy maintenance can help people with extensive-stage small cell lung cancer who have already completed 4-6 cycles of standard chemoimmunotherapy without the cancer getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have extensive-stage small cell lung cancer confirmed by a biopsy.
- You have had at least 4 to 6 cycles of first-line chemoimmunotherapy and your cancer did not get worse.
- You have at least one tumor that can be measured on scans.
- You are able to take care of yourself most days (ECOG score 0-2).
- Your life expectancy is at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (sintilimab and anlotinib) for people with extensive-stage small cell lung cancer that has gotten worse after prior immunotherapy. The goal is to see if this combination can help control the cancer.
This study tests a combination of an oral targeted therapy (anlotinib) with a liposomal form of chemotherapy and an immunotherapy drug as maintenance treatment for extensive-stage small cell lung cancer after initial treatment. It aims to keep the cancer from growing again.
This trial tests a combination of two drugs, toripalimab and anlotinib, as maintenance therapy after initial treatment for extensive stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from growing for as long as possible.
This trial tests a combination of the targeted drug bemotuzumab, chemotherapy, and anlotinib (which blocks blood vessel growth) followed by radiation therapy for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this approach helps control the cancer.
This trial tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, for people with extensive-stage small cell lung cancer that has worsened after at least two cycles of standard chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.